Adiponectin acts as an endogenous antithrombotic factor. However, the mechanisms underlying the inhibition of platelet aggregation by adiponectin still remain elusive. The present study was designed to test whether adiponectin inhibits platelet aggregation via attenuating oxidative/nitrative stress. Adult rats were fed a regular or high-fat diet for 14 weeks. The platelet was immediately separated and stimulated with recombinant full-length adiponectin (rAPN) or not. The platelet aggregation, nitric oxide (NO) and superoxide production, endothelial nitric oxide synthase (eNOS)/inducible NOS (iNOS) expression, and antioxidant capacity were determined. Treatment with rAPN inhibited hyperlipidemiainduced platelets aggregation (P<0.05). Interestingly, total NO, a crucial molecule depressing platelet aggregate and thrombus formation， was significantly reduced, rather than increased in rAPN-treated platelets. Treatment with rAPN markedly decreased superoxide production (-62%, P<0.05) and enhanced antioxidant capacity (+38%, P<0.05) in hyperlipidemic platelets. Noticeably, hyperlipidemia-induced reduced eNOS phosphorylation and increased iNOS expression was significantly reversed following rAPN treatment (P<0.05, P<0.01, respectively). Taken together, these data suggest that adiponectin is an adipokine that suppresses platelet aggregation by enhancing eNOS activation and attenuating oxidative/nitrative stress including blocking iNOS expression and superoxide production.
Introduction
Metabolic syndrome (MS) is characterized by a series of metabolic and hemodynamics alterations, which increase the incident of endothelial damage and atherosclerosis, becoming the leading cause of cardiovascular disease. (Hulthe et al. 2000; Sakkinen et al. 2000) Of note, hyperlipidemia, the critical composition of metabolic syndrome, is closely related to atherosclerosis and formation of thrombus. Dyslipidemia is accompanied by platelet hyperactivity, hypercoagulability with increased factor VII, and hypofibrinolysis with increased plasminogen activator inhibitor (PAI)-1. (Juhan-Vague & Vague 1990 ) The increased flux of nonesterified fatty acids (NEFAs) from the adipocytes increases tissue factor (TF) and PAI-1 levels and enhances platelet aggregation; All of these obviously promote thrombosis. (Eckel et al. 2002) Adiponectin is a cytokine predominantly secreted from adipose tissue and abundantly presents in plasma. Numerous studies have shown that plasma levels of adiponectin decrease in obesity, type 2 diabetes, and patients with coronary artery disease (CAD) (Hotta et al. 2000; Matsuzawa et al. 2004) . In adiponectin knockout (APN-KO) male mice, an accelerated thrombus formation has been observed. Adenovirus-mediated supplementation of adiponectin attenuates the enhanced thrombus formation. (Kato et al. 2006 ) Decreased adiponectin serum levels in patients with essential hypertension correlate well with changes in ADP-induced conventional platelet aggregation (Ekmekci et al. 2008) , this association may potentially contribute to future thrombus formation and higher risks for cardiovascular events in those patients. These data suggest that adiponectin acts as an endogenous antithrombotic factor. However, the mechanisms underlying the inhibition of platelet aggregation by adiponectin still remain largely elusive.
Platelet activation occurs through the stimulation of a large number of exquisitely integrated positive signaling pathways that ensure rapid activation at sites of vascular injury.
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Platelets may also generate nitric oxide (NO), although the presence of NO synthase (NOS) and the role of platelet-derived NO are both controversial.(Naseem & Riba 2008) It was suggested that platelet-derived NO depress platelet aggregate and thrombus formation. (Freedman et al. 1997; Freedman et al. 1999 ) At the same time, platelet-derived NO has been suggested to be a critical component of the platelet activation pathway in response to von Willebrand factor (VWF) and thrombin. (Li et al. 2003; Li et al. 2006) Regardless of the role of NO, all of these studies agree that NO mediates platelet actions through the stimulation of sGC and downstream activation of PKG, although they may be critical for the interpretation of the potential role of this related enzyme in platelets.
Furthermore, to the best of our knowledge, the possibility that adiponectin may play a crucial role in protection of vasculature from hyperlipidemia-promoted platelet aggregation and thrombosis formation has never been studied.
In this study, we have provided the first evidence that as an antithrombotic factor, adiponectin inhibits hyperlipidemia-induced platelet aggregation via eNOS/NO pathway.
Material and methods

Animals
All the experimental procedures were in accordance with the National Institutes of Health guidelines and were approved by the local authorities for animal research. Twenty male Sprague-Dawley rats (8 wk old) were randomized to receive a regular chow diet or a high-fat supplemented diet (detailed composition: 1% cholesterol, 10% lard, 10% yolk powder, 0.2% porcine cholate, 78.8% regular chow). Food and water were provided ad libitum, and animals were maintained in a temperature-controlled barrier facility with a 12:12-h light-dark cycle. Fourteen weeks later, animals were anesthetized by intraperitoneal administration of 20% urethane. Caval blood was withdrawn, the platelet was immediately separated, and lipid profile, glucose, and insulin levels were determined as described below.
Plasma lipid determinations
Plasma cholesterol and triglyceride levels were determined by a biochemistry analyzer (Cobas Integra 400 Plus, Roche) in accordance with the manufacturer's instructions.
Isolation of rat platelets
Rat platelets were isolated as the method described previously .
Briefly, caval blood was taken using acid citrate dextrose (ACD: 29.9 mM sodium citrate, 113.8 mM glucose, 72.6 mM NaCl and 2.9 mM citric acid, pH 6.4) as anticoagulant.
Platelet-rich plasma (PRP) was obtained by centrifugation of whole blood at 200g×20 min.
Washed platelets (WP) were isolated from PRP by centrifugation at 800g×12 min in the presence of prostaglandin E1 (PGE1; 50 ng/mL). The platelet pellet was resuspended at a concentration of 2×10 8 platelets/mL in modified Tyrodes buffer (150 mM NaCl, 5 mM HEPES, 0.55 mM NaH 2 PO 4 , 7mM NaHCO 3 , 2.7 mM KCl, 0.5 mM MgCl 2 and 5.6 mM glucose, pH 7.4).
Platelet aggregation
Platelet aggregation was analyzed by a improved turbidimetric method (Born 1962) . Platelet aggregation was also examined by using a fluorescence microscope and followed immunofluorescence detection procedures described previously (Karpman et al. 2001 ). Treated platelets were fixed with 1% paraformaldehyde at 25°C for 30 min. After fixation, platelets were seed onto glass slides. Coated glass slides were washed three times with PBS, and fluorescein isothiocyanate (FITC)-conjugated rabbit anti-rat CD9 monoclonal antibody was added and incubated at 37°C for 1 h. Slides were washed four times in PBS, and covered with fluorescent mounting gel (Biomeda, Vancouver, Canada) before being examined under an immunofluorescence microscope. For each slide, 10 fields were randomly chosen and using a defined rectangular field area (20 × objective), a total of 100 platelets per field were counted. The aggregation index was determined. The assays were performed in a blinded manner.
Total NO production measurement
Platelets total NO production was determined by measuring the concentration of nitrite, a stable metabolite of NO in vitro, with a modified Griess reaction method (Cosentino et al. 1997) . Briefly, control platelets or hyperlipidemic platelets were stimulated with vehicle, rAPN (10 μg/mL), or rAPN addition of L-NMMA as above, 100 μl of culture medium was taken and mixed with an equal volume of modified Griess reagent (1% sulfanilamide, 0.1% naphthylethylenediamine dihydrochloride, and 2% phosphoric acid). After 10 min of incubation at room temperature, the resultant chromophore was spectrophotometrically determined at 540 nm using a spectrophotometer (Spectra-Max 190, Molecular Device). The nitrite concentrations in the samples were calculated from freshly prepared nitrite standard curves made from sodium nitrite with the same medium.
Determination of eNOS and iNOS expression by Western blot
Platelets were sonicated in lysis buffer. 
Determination of platelets antioxidant capacity
Platelets were sonicated in 0.9% NaCl solution (1:10, wt/vol), and centrifuged at 3,000 g for 5 min. The pellet was discarded. Total antioxidant capacity was determined with a spectrophotometric assay kit (Nanjing Jiancheng Bioengineering Institute), following the manufacture's instruction. In brief, 30 μl of supernatant was added to the reaction buffer containing xanthine, xanthine oxidase, and hydroxylamine. After 40 min of incubation at 37°C, accumulation of nitrite was quantified by the Griess reaction. Platelets antioxidant capacity is inversely related to the concentration of nitrate. Results were normalized against the mean value of control and expressed as fold changes.
Quantification of platelets superoxide production
Superoxide production from platelets was measured by flow injection chemiluminescence as described previously (Yao et al. 2004) . Superoxide production was expressed as chemiluminescence intensity (CI) per microgram of protein (CI/μg protein).
Statistical analysis
Values are presented as means±SEM. Data were analyzed with one-way ANOVA (GraphPad Software, San Diego, CA). A probability value of P＜0.05 was considered to be statistically significant.
Results
Plasma lipid profile
Total cholesterol and triglyceride levels were found to be significantly higher in HF fed rats than those fed with control diet (2.0±0.1 vs 1.6±0.1 of Con, P<0.01 and 1.5±0.3 vs 1.1±0.3 of Con, P<0.05, respectively, n=8-10 animals/group.).
Treatment with rAPN inhibited hyperlipidemia-induced platelets aggregation
As illustrated in Fig. 1, hyperlipidemia 
Treatment with rAPN decreased hyperlipidemia-induced NO overproduction
NO has been shown responsible for endothelial vasorelaxation and inhibition of platelet adhesion and aggregation (Riddell & Owen 1999) . We attempted to obtain direct evidence that treatment with rAPN may increase NO production and thus inhibit hyperlipidemia-induced platelets aggregation. Surprisingly, although treatment of platelets with rAPN significantly decreased platelets aggregation, this treatment reduced, rather than increased, total NO production (P<0.05, Fig. 3 ). This paradoxical result suggests that more complex signaling mechanisms are involved in the protective effect of rAPN against hyperlipidemia-induced platelets aggregation.
Treatment with rAPN increased eNOS phosphorylation and reduced iNOS expression in hyperlipidemic platelets
Although adiponectin has been shown to stimulate NO production in cultured platelets by phosphorylating eNOS (Milward et al. 2006) , treatment with rAPN did not increase but reduced total NO production in hyperlipidemic platelets (Fig. 3) . These results suggest that the overall effect of rAPN on total NO production may involve a complex regulation of rAPN on different forms of NOS under hyperlipidemic conditions. To directly investigate this novel possibility, the effect of rAPN on eNOS phosphorylation and iNOS expression was determined. As summarized in Fig. 4 , a significant reduction in eNOS phosphorylation (P<0.05) and a marked increase in iNOS expression (P<0.01) were observed in hyperlipidemic platelets. Pretreatment with rAPN almost completely normalized eNOS phosphorylation (P<0.05) and significantly reduced iNOS expression (P<0.01) in hyperlipidemic platelets. These results demonstrated that rAPN had opposite effects on p-eNOS and iNOS expression, and this differential regulatory role may explain the paradoxical finding that rAPN significantly inhibited platelets aggregation but reduced total NO production.
Treatment with rAPN significantly reduced superoxide overproduction and enhanced antioxidant capacity in hyperlipidemic platelets
The above-mentioned results demonstrated that overproduction of NO in hyperlipidemic platelets is due to overexpression of iNOS protein. However, increase in NO production failed to inhibit platelets aggregation, suggest that increased NO destruction may be responsible for hyperlipidemic platelets aggregation. In addition, our novel observation that rAPN inhibited platelets aggregation without increasing NO production indicates that 11 rAPN may reduce platelets aggregation by preserving bioactive NO. To obtain direct evidence to support this hypothesis, additional experiments were performed. As summarized in Fig. 5A , a 2.5-fold increase in superoxide production was observed in platelets isolated from hyperlipidemic animals, and treatment with rAPN almost abolished (62% reduction compared with vehicle-treated platelets, P<0.05) the superoxide overproduction observed in hyperlipidemic platelets. Moreover, hyperlipidemia-induced reduction in total antioxidant capacity was significantly preserved after rAPN treatment (38% increase compared with vehicle-treated platelets, P<0.05, Fig. 5B ).
Discussion
The present study yields several critical new observations. First, we have observed for the first time that acute treatment with rAPN significantly attenuated hyperlipidemia-induced platelets aggregation. Second, we have provided direct evidence that inhibiting superoxide production, suppressing iNOS-mediated NO overproduction and preserving NO from destruction are the major mechanisms by which adiponectin exerts its antithrombotic effect.
This result not only provides additional evidence that reduced adiponectin in metabolic disorders contributes to the formation of thrombus, but raises the possibility that therapeutic application of rAPN may be a useful treatment of metabolic disorders with atherosclerosis.
The close correlation among obesity, the metabolic syndrome, and atherosclerosis are 
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